Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

Option Agreement with Sanofi. At the ASN Kidney Week 2013 meeting, Regulus and its strategic alliance partner, Sanofi, and its collaborator at the University of Washington, presented positive preclinical data in a poster and oral presentations demonstrating that miR-21 plays an important role in the disease progression of Alport Syndrome in collagen 4A3 deficient mice. According to the National Institutes of Health, Alport Syndrome occurs in approximately 1 in 50,000 newborns. Alport Syndrome is a genetic condition characterized by kidney disease, hearing loss, and eye abnormalities. The kidneys become less able to function as this condition progresses, resulting in end-stage renal disease. These results demonstrate that treatment with an anti-miR-21 candidate significantly improved renal function, significantly reversed regulated genes and pathways associated with renal pathology, and increased the lifespan of the mice by 20 percent.
Regulus and Sanofi entered into an Option Agreement to enable exclusive negotiation of a potential new co-development and commercialization agreement. Under the terms of the Option Agreement, Regulus has the exclusive right to negotiate with Sanofi to enter into a co-development and commercialization agreement for certain miR-21 anti-miRs in oncology and in Alport Syndrome. Regulus anticipates that the second microRNA candidate to be nominated for clinical development by the end of the year under its 'Road to the Clinic' strategy may come from the miR-21 fibrosis program.
  • Achieved Significant Progress in Strategic Alliance with AstraZeneca; New Pre-Clinically Validated microRNA Oncology Target Selected. Under Regulus' strategic alliance to discover, develop, and commercialize microRNA therapeutics with AstraZeneca, an undisclosed, pre-clinically validated oncology target was selected by AstraZeneca. The companies continue to collaborate on three exclusive microRNA targets in cardiovascular and metabolic
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
    2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
    3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
    4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
    6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
    7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
    9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    11. Regulus to Present at Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... N.J. , Aug. 31, 2015  ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today it has completed ... the Data Review Committee (DRC) earlier this year, ... SGX942 is a first-in-class innate defense regulator (IDR) ...
    (Date:8/31/2015)... -- Premune and Innovet today ... agreement for Redonyl ® Ultra. The product, which ... dermatology market, is a nutritional supplement based on PEA-um ... dogs and cats. Redonyl ® Ultra is currently ... been received positively in the country by veterinarians and ...
    (Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
    Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
    ... BNVI ), a pharmaceutical company focused on the ... health and cancer, today announced that Dr. Isaac Cohen, O.M.D., ... Cowen and Company 31st Annual Healthcare Conference at 9:30 a.m. ... held at the Boston Marriott Copley Place, in Boston, Massachusetts. ...
    ... March 7, 2011   PDL BioPharma, Inc. (PDL) ... the first quarter ending March 31, 2011 of approximately $83 ... the first quarter of 2010, an expected 34 percent year-over-year ... million settlement received from UCB Pharma S.A. (UCB) in January ...
    Cached Medicine Technology:Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
    (Date:8/31/2015)... ... August 31, 2015 , ... ... with a ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber ... appointments via AdvantaClean’s National Call Center and website since Aug. 17. , The ...
    (Date:8/31/2015)... ... 2015 , ... American Family Care (AFC), the nation’s leading ... in Tennessee with the opening of a new urgent care facility at 9203 ... in Tennessee, and 148th in the U.S. overall. , “We’re excited to continue ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Kognito , a ... their competencies in managing challenging conversations, announced today that Glenn Albright, Ph.D., the ... of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit taking ...
    (Date:8/31/2015)... ... August 31, 2015 , ... In preparation for this November’s National Family ... BEAN™ personal sound amplifier, is offering caregivers “7 Reasons to Care about Hearing Health.” ... coping with a variety of home healthcare challenges, specifically as they relate to caring ...
    (Date:8/31/2015)... ... August 31, 2015 , ... ... for physicians and allied health professionals dedicated to using lifestyle as a ... the establishment of the Lifestyle Medicine Lifetime Achievement and Trailblazer Awards, with ...
    Breaking Medicine News(10 mins):Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3
    ... in human cases of bird flu, causing increasing fear of ... in the scientific community to combat this impending and much ... risen since October 5 when scientists from the U.S. Army ... similarities between the bird flu strain in Asia, called H5N1, ...
    ... flu pandemic has created a stir worldwide with US President ... developers to speed up the process of developing a vaccine ... than 80 countries and international organizations met in Washington on ... officials including those from the World Health Organization (WHO) have ...
    ... Online Publication, released on the 5th of October, which ... diseases, has a comprehensive report on the threat of ... by Union Health Minister Dr Anbumani Ramadoss, the need ... challenge of chronic diseases in India was highlighted, stating ...
    ... Though technologic developments bring social and economic benefits ... are difficult to predict and manage. With rapid ... communications, children are increasingly exposed to EMFs at ... childhood leukemia and exposure to extremely low frequency ...
    ... found a new gene based test for identifying DNA fusion, ... research team is focusing on detection of genes // linked ... called as Acute Lymphoblastic Leukemia (ALL). The researchers took more ... is given by chemotherapy which kills the leukemia cells and ...
    ... one of life’s most distressing events, bringing in its wake ... reaction to the disease, but could have grave consequences. Because ... have an impact not only on the progression, but also ... in the ordinary course of human life, have been shown ...
    Cached Medicine News:Health News:Strategies to prevent the rising tide of the epidemic of chronic diseases 2Health News:Hazards of Electromagnetic Fields for children 2Health News:Depression May Be A Risk Factor For Cancer Initiation 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: